These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9301631)

  • 1. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia.
    Marais AD; Firth JC; Bateman ME; Byrnes P; Martens C; Mountney J
    Arterioscler Thromb Vasc Biol; 1997 Aug; 17(8):1527-31. PubMed ID: 9301631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G; Di Garbo V; Abruzzese G; Campisi D; De Simone R; Raneli G; Licata G
    Int Angiol; 2006 Mar; 25(1):26-34. PubMed ID: 16520721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P; Heinonen T; Shurzinske L; Black DM
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia.
    Hoogerbrugge N
    J Intern Med; 1998 Aug; 244(2):143-7. PubMed ID: 10095800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia.
    Castaño G; Mas R; Fernández L; Illnait J; Mesa M; Alvarez E; Lezcay M
    Drugs Aging; 2003; 20(2):153-63. PubMed ID: 12534315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia.
    Marais AD; Naoumova RP; Firth JC; Penny C; Neuwirth CK; Thompson GR
    J Lipid Res; 1997 Oct; 38(10):2071-8. PubMed ID: 9374129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of atorvastatin on serum lipids and lipoproteins in patients with homozyous familial hypercholesterolemia undergoing LDL-apheresis therapy.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Oi K; Kubo H; Sakai S; Mikami Y; Imai T; Ito T; Kato H; Endo M; Sato I; Suzuki Y; Hori H
    Atherosclerosis; 2000 Nov; 153(1):89-98. PubMed ID: 11058703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia.
    Goldammer A; Wiltschnig S; Heinz G; Jansen M; Stulnig T; Hörl WH; Derfler K
    Metabolism; 2002 Aug; 51(8):976-80. PubMed ID: 12145769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia.
    Gandelman K; Glue P; Laskey R; Jones J; LaBadie R; Ose L
    Pediatr Cardiol; 2011 Apr; 32(4):433-41. PubMed ID: 21259004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of atorvastatin on erythrocyte membranes and serum lipids in patients with type-2 hypercholesterolemia.
    Koter M; Broncel M; Chojnowska-Jezierska J; Klikczynska K; Franiak I
    Eur J Clin Pharmacol; 2002 Nov; 58(8):501-6. PubMed ID: 12451426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
    Wierzbicki AS; Lumb PJ; Chik G; Crook MA
    Am J Cardiol; 2000 Sep; 86(5):547-9, A9. PubMed ID: 11009276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol--a multinational, multicenter, double-blind study.
    Wu CC; Sy R; Tanphaichitr V; Hin AT; Suyono S; Lee YT
    J Formos Med Assoc; 2002 Jul; 101(7):478-87. PubMed ID: 12353340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.
    Davidson M; Ma P; Stein EA; Gotto AM; Raza A; Chitra R; Hutchinson H
    Am J Cardiol; 2002 Feb; 89(3):268-75. PubMed ID: 11809427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.